Adding Pembrolizumab To Preoperative Radiotherapy and Surgery Improves DFS for Patients with Stage III Soft Tissue Sarcomas of the Extremity By Ogkologos - December 2, 2024 929 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SU2C-SARC032 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Phase II LCMC3 Study of Neoadjuvant Atezolizumab Met Primary Endpoint with... September 16, 2022 Detecting multiple cancers with a ‘simple’ blood test: Where are we? April 14, 2022 Clinical Benefit of Pembrolizumab in Patients with Previously Treated Advanced Clear... March 4, 2025 Managing Cancer Pain: Are Better Approaches on the Horizon? January 23, 2019 Load more HOT NEWS 27-Year-Old Thought She Was Injured Falling Off A Horse, But Then... More Than One in 10 Patients With Lung Cancer Do Not... What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials ESMO Breast Cancer Congress 2022
